MEDI Myconic Capital Corp

KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments and associated research, is pleased to announce that it has recently engaged a small number of arm’s length service providers to assist with investor relations, media and public awareness.

First, CanaComGroup (“CCG”) has been engaged to provide an investor awareness program to engage with the online community and help achieve a better understanding of Ketamine One (“CCG Services”) for a period of six months, subject to the terms of the service agreement (the “CCG Agreement”) entered into between the MEDI and CCG. Pursuant to the CCG Agreement, CCG will be paid an up-front cash amount of $50,000 plus Goods and Services Tax (“GST”) for the CCG Services to be provided over the six-month term.

Second, the Company has engaged CFN Enterprises Inc. (“CFN Media”), to provide investor relations and media services (the “CFN Media Services”) for an initial term of three months, subject to the terms of the service agreement (the “CFN Media Agreement”) entered into between the MEDI and CFN Media. Pursuant to the terms of the CFN Media Agreement, CFN Media will be paid an aggregated cash fee of US $27,000 over the three-month term. For more information about CFN Media, please visit https://www.cannabisfn.com/.

Third, the Company has engaged Proactive Investors North America Inc. (“Proactive”), to assist the Company in enhancing its online profile with the global investment community (the “Proactive Services”) for a period of thirteen months, subject to the terms of the service agreement (the “Proactive Agreement”) executed between the Company and Proactive. Pursuant to the terms of the Proactive Agreement, Proactive will be paid an up-front cash amount of $25,000 plus GST for the Proactive Services to be provided over the 13-month term.

The Company also announces that subject to acceptance by the NEO Exchange, it has granted an aggregate of 50,000 stock options (the “Options”) to a director to purchase up to 50,000 common shares of the Company at a price of $1.70 per common share for a period of five years from the date of grant, pursuant to its Stock Option Plan that was approved by shareholders on February 21, 2021. 50% of the Options vest six months from the date of grant with the remaining 50% of the Options vesting twelve months after the date of the grant.

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

"Robert Meister"Robert Meister, CEO and Director

For further information, please contact:

Nick Kuzyk, Investor RelationsTel: 1-844-PHONE-K1 (1-844-746-6351)Email: IR@ketamine.one Web: www.ketamine.one Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.